-
Mashup Score: 1Paper: Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma - 6 hour(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Exploring T Cell Redirecting Therapies, Mutation Profiles and Early Relapse Hematology Disease Topics & Pathways: Research, Adult, Plasma Cell Disorders, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Treatment Considerations, Biological therapies, Real-world evidence, Adverse Events, Lymphoid Malignancies, Study Population, Human Kai Rejeski, MD 1,2, Doris K. Hansen,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Paper: NF-Kb Pathway Activation Driven By TRAF3 Loss Mediates Resistance to Anti-BCMA T-Cell Based Therapies in Multiple Myeloma - 15 hour(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Resistance and Response to Anti-Myeloma Therapies Hematology Disease Topics & Pathways: Research, Fundamental Science, Apoptosis, Translational Research, Plasma Cell Disorders, Genomics, Diseases, Immune mechanism, Immunology, Lymphoid Malignancies, Biological Processes, Molecular biology David Jung, BSc 1 *, Holly Lee, MD 1, Sejal Chikhale 1 *, Mansour Poorebrahim, PhD 1 *,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
NF-Kb Pathway Activation Driven By TRAF3 Loss Mediates Resistance to Anti-BCMA T-Cell Based Therapies in Multiple Myeloma [Dec 8, 2024] Jung et al. #ASH24 Abst 591 https://t.co/bKhROHNumD #mmsm #CARTcell
-
Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma [Dec 9, 2024] Rejeski et al. #ASH24 895 https://t.co/mNeaEM1atO #mmsm #CARTcell HT @jmikhaelmd